NCT06618963
Effect of Omalizumab in the Skin of Food Allergy Patients
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 27 words
- Primary completion date changed from estimate of Sep 2026 to Nov 3, 2026
- Secondary endpoints: details revised at 3 of 5 entries
- Study description expanded, about 5 words
- Notable Trial status: Not Yet Recruiting to Recruiting
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Lipidomic analysis
Timeframe: 5 months
Metabolomic analysis
Timeframe: 5 months
Proteomic analysis
Timeframe: 5 months
Cytokine analysis
Timeframe: 5 months
Measurement of Transepidermal Water Loss
Timeframe: 5 months
Secondary (5)
Measurement of Transepidermal Water Loss in non Food-Allergic Subjects
Lipidomic analysis in non Food-Allergic participants
Metabolomic analysis in non Food-Allergic Participants
Proteomic analysis in non Food-Allergic Participants
Cytokine analysis
Arms and interventions
Participants with Food AllergyActive comparator
This group will receive 4 months of Omalizumab treatment, and undergo regular skin barrier assessments.
Participants without Food AllergyNo intervention
This group will undergo skin barrier assessment.
Drugs: Omalizumab Injection
Sites
1 site in 1 country
- National Jewish HealthDenver, Colorado, United States